RECRUITING HAEMATOLOGY TRIALS
Last Updated 31 August 2023 12:38 pm
GCT3013-02
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
CURRENT SLOT STATUS
Available
PHASE
Phase I/II
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
POD24 FL
R/R DLBCL eligible for ASCT
IP CLASS
Targeted
PRT2527-02
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies
CURRENT SLOT STATUS
Available
PHASE
I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL, CLL
IP CLASS
CDK9 Inhibitor
DZ2022B0002
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
CURRENT SLOT STATUS
Available
PHASE
Phase I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL, CLL
IP CLASS
BTKi
SLN124-004
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera
CURRENT SLOT STATUS
Available
PHASE
I/II
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
PV
IP CLASS
siRNA
ASTX660-03
A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma
CURRENT SLOT STATUS
Available
PHASE
Phase I/II
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
PTCL
IP CLASS
AP Antagonist + Hypomethalation Agent/CDA Inhibitor
75348780LYM1001
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL
CURRENT SLOT STATUS
Waitlist
PHASE
I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL, CLL
IP CLASS
Bispecific
MoST 16 Pamiparib
Single arm, open label, signal seeking, phase II trial of pamiparib in patients with relapsed/refractory myeloid haematological malignancy with aberrant germline or somatic DNA repair pathway function.
CURRENT SLOT STATUS
Available
PHASE
II
REQUIRED MOLECULAR TARGET
DNA Repair Pathway Mutation
TUMOUR TYPES
AML, MDS
IP CLASS
PARP Inhibitor
BGB-11417-103
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
CURRENT SLOT STATUS
Waitlist
PHASE
Ia/Ib
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
AML, MDS
IP CLASS
BCL-2 Inhibitor
80948543LYM1001
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL
CURRENT SLOT STATUS
Waitlist
PHASE
I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL, CLL
IP CLASS
Trispecific
LOXO-BTK-20019
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321
CURRENT SLOT STATUS
Available
PHASE
III
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
MCL
IP CLASS
BTKi
BGB-11417-101
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
CURRENT SLOT STATUS
Available
PHASE
I
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL, CLL
IP CLASS
BCL-2 Inhibitor + BTK inhibitor
DR-01-ONC-001
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
CURRENT SLOT STATUS
Available
PHASE
I/II
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
T-Cell Lymphoma, LGLL
IP CLASS
Targeted
BGB-16673-101
A Phase I/Ib Open-Label Dose Escalation and Expansion Study of Bel-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies
CURRENT SLOT STATUS
Available
PHASE
I/Ib
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
NHL, CLL
IP CLASS
BCL-2 Inhibitor + BTKi, Targeted
218670 (DREAMM20)
A Phase 1/2 open-label, multicentre, dose escalation and expansion study to investigate the safety, tolerability, and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma.
CURRENT SLOT STATUS
Opening Soon
PHASE
I/II
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
MM
IP CLASS
Anti BCMA Antibody/ADC +/- SOC Therapies
C1071005
A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
CURRENT SLOT STATUS
Opening Soon
PHASE
III
REQUIRED MOLECULAR TARGET
N/A
TUMOUR TYPES
MM
IP CLASS
BCMAxCD3 Bispecific +/- CD39 mAb VS IMiD + CD39 mAb + Corticosteroid